Document is current
Any future updates will be listed below
-
Authors
Sentilhes, Loïc
Madar, Hugo
Ifrah, Amélie
Chrétien, Jean-Marie
Deneux-Tharaux, Catherine
,
- License Information
-
More Information
Article History
Received: 27 February 2025
Accepted: 4 May 2025
First Online: 30 May 2025
Declarations
:
: This research study was designed and is implemented in accordance with the Declaration of Helsinki’s principles on studies involving human subjects.TRAAPREVIA trial was approved.- by the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) (national agency for drug safety), March 12, 2020.- by the following Approval Committee: Comité de Protection des Personnes (CPP South East III) (Committee for protection of persons involved in biomedical research), March 5, 2020. Informed written consent will be obtained from all participants.
: Not applicable.
: Dr. Loïc Sentilhes reports receiving lecture fees from Norgine, and lecture and consulting fees from Ferring Pharmaceuticals, GlaxoSmithKline, Pfizer, Organon and Bayer. The other authors did not report any potential conflicts of interest.
